Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE): Arena Pharmaceuticals, Inc. (ARNA) Pushes Forward

As much as I think Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)‘ investors are overestimating the near-term potential for the biotech’s obesity drug Belviq, I think it’s underestimating the potential for the pipeline.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s market cap is about $200 million less than its closest competition, VIVUS, Inc. (NASDAQ:VVUS) , but Arena has four other drugs in its pipeline. VIVUS, Inc. (NASDAQ:VVUS) doesn’t have any; it does have an erectile dysfunction drug, Stendra, but considering that it received FDA approval more than a year ago and VIVUS, Inc. (NASDAQ:VVUS) still hasn’t launched it, the biotech doesn’t seem to think it’s all that valuable.

Investors’ focus on Belviq is understandable:

  • Belviq is already approved. The pipeline drugs could flop in clinical trials.
  • Belviq is producing royalties and manufacturing revenue from Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s partner, Eisai, right now. The pipeline drugs are years away from generating revenue.

But Arena’s long-term valuation has to take the pipeline into account.

Fortunately, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is making progress, moving its pipeline closer to generating revenue for the company. On Wednesday, Arena said it completed a phase 1b trial for APD811, a treatment for pulmonary arterial hypertension, a form of high blood pressure.

The trial was only in healthy volunteers, but it seems to have met its goals for safety, tolerability, and pharmacokinetics, which measures how much of the drug is taken up by the body and how quickly it’s removed.

The next step is for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to start a phase 2 trial in patients with pulmonary arterial hypertension. We may see two phase 2 trials, one to try and nail down the correct dose and then a second with more patients at the dose the company plans to use for phase 3 trials. Sometimes they’re run as one phase 2a/b trial.

The potential market for APD811 isn’t nearly as large as the obesity market. Only 0.001% of Americans have pulmonary arterial hypertension compared with 35% of Americans who are obese.

Despite the small population, it’ll be a lot easier for Arena to get doctors to prescribe a pulmonary arterial hypertension drug than an obesity drug. Obesity creates long-term problems for patients, but there’s generally no rush to treat patients immediately. By contrast, a little less than half of pulmonary arterial hypertension patients don’t survive five years from diagnosis.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) should also be able to charge more for APD811 than it can for Belviq, creating a decent market despite the small number of people with pulmonary arterial hypertension. Pfizer Inc. (NYSE:PFE)‘s Revatio, for instance, brought in more than half a billion dollars last year before it went generic.

Beyond generic Revatio and a few other options, APD811’s main competition will be United Therapeutics Corporation (NASDAQ:UTHR) Remodulin, which works through the same general mechanism acting on the prostacyclin receptor. Fortunately, APD811 is taken orally while Remodulin needs to be infused, giving it a substantial advantage if the efficacy is the same or better.

The article Arena Pharma Pushes Forward originally appeared on and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. 

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.